Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Vaso-Occlusive Crisis and Thrombosis Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SELP drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SELP ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View SELP Products |
| Gene Delivery | SELP Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and flow cytometry validation. |
View SELP Products |
| Benchmark Ab | Anti-SELP (Sequence of Crizanlizumab) Recombinant humanized IgG2 positive control. |
View SELP Products |
| Validator | SELP siRNA Set For target knockdown verification in endothelial cell assays. |
View SELP Products |
| Related Target A | SELPLG (PSGL-1 / CD162) Primary physiological ligand mediating leukocyte rolling and adhesion. |
View SELPLG Products |
| Related Target B | SELE (E-selectin / CD62E) Homologous selectin family member for off-target and selectivity counter-screening. |
View SELE Products |
| Related Target C | SELL (L-selectin / CD62L) Leukocyte selectin used to assess pan-selectin cross-reactivity. |
View SELL Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Calcium-Dependent Conformation | HEK293 Expressed SELP preserving native C-type lectin domain folding and calcium-binding activity. |
| Selectivity Counter-Screening | Recombinant SELE and SELL panel available for high-throughput selectivity profiling. |
| Lack of Controls | Sequence-verified Crizanlizumab biosimilar benchmark antibody included. |
| False Positives | Sequence-verified siRNA pool included for target specificity validation. |
Live SELP R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of SELP (P-selectin) is a validated clinical strategy, highlighted by the approval of Crizanlizumab for preventing vaso-occlusive crises (VOCs) in patients with sickle cell disease (SCD). Beyond hemoglobinopathies, the R&D landscape is expanding into acute myocardial infarction, deep vein thrombosis (DVT), and tumor metastasis microenvironments, where P-selectin facilitates platelet-tumor cell interactions.
The race for SELP therapeutics is intensifying, with major players shifting focus from traditional mAbs to small-molecule glycomimetics and long-acting biologics. As first-generation therapies reach the clinic, the next wave of R&D is targeting multi-valent selectin inhibitors and bispecific antibodies to enhance anti-adhesive efficacy without compromising systemic immune surveillance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | Novartis | Sickle Cell Disease (SCD), Vaso-Occlusive Crises (VOC) | Ligand-blocking assays (Need high-purity SELP and SELPLG proteins) |
| Small Molecule Glycomimetics | GlycoMimetics | Thrombosis, Vaso-occlusion, Oncology | Competitive binding assays (Need native glycosylated SELP C-type lectin domain) |
| Bispecific & Multi-specifics | Academic / Biotech Startups | Inflammatory Diseases, Ischemia-Reperfusion Injury | Simultaneous binding kinetics (Need SELP and SELE/SELL ortholog panel) |